Verastem

Verastem, Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative therapies aimed at improving the survival and quality of life for cancer patients. The company markets COPIKTRA, an oral inhibitor that targets specific PI3K pathways, approved for treating adult patients with relapsed or refractory chronic lymphocytic leukemia and follicular lymphoma after prior therapies. Verastem is also advancing its pipeline with defactinib, a focal adhesion kinase inhibitor, which is being tested in combination with immunotherapies for various cancer types, including pancreatic and non-small cell lung cancers. Founded in 2010 and based in Needham, Massachusetts, Verastem has established collaborations with Yakult Honsha Co., Ltd. and CSPC Pharmaceutical Group Limited to enhance its research and development efforts.